AAPL315.32-0.90 (-0.28%) ▼|ABBV248.08-1.83 (-0.73%) ▼|ABT93.93-0.47 (-0.50%) ▼|ACN135.23-3.83 (-2.75%) ▼|ADBE223.64+0.99 (+0.44%) ▲|AMAT602.50+13.84 (+2.35%) ▲|AMD557.89+11.17 (+2.04%) ▲|AMGN363.39-0.23 (-0.06%) ▼|AMT168.59+3.59 (+2.18%) ▲|AMZN245.34-1.70 (-0.69%) ▼|AVGO399.97-1.14 (-0.28%) ▼|AXP350.58+3.86 (+1.11%) ▲|BA222.28-0.83 (-0.37%) ▼|BAC59.67+0.42 (+0.71%) ▲|BKNG178.39+2.87 (+1.64%) ▲|BLK1,036.11+16.43 (+1.61%) ▲|BMY57.58-0.36 (-0.62%) ▼|BNY151.92-0.34 (-0.22%) ▼|BRK-B493.71-1.74 (-0.35%) ▼|C140.79+1.22 (+0.87%) ▲|CAT952.41+14.02 (+1.49%) ▲|CL92.24+1.23 (+1.35%) ▲|CMCSA23.57+0.23 (+0.96%) ▲|COF201.52+1.42 (+0.71%) ▲|COP109.04+1.02 (+0.94%) ▲|COST916.25+3.28 (+0.36%) ▲|CRM163.32+0.82 (+0.50%) ▲|CSCO121.31+3.00 (+2.54%) ▲|CVS104.15+1.34 (+1.30%) ▲|CVX176.40+2.35 (+1.35%) ▲|DE586.86-6.04 (-1.02%) ▼|DHR199.05+3.07 (+1.57%) ▲|DIS95.62-0.55 (-0.57%) ▼|DUK125.48+0.22 (+0.18%) ▲|EMR138.88+1.08 (+0.78%) ▲|FDX314.69+3.85 (+1.24%) ▲|GD375.06+0.46 (+0.12%) ▲|GE359.27+0.23 (+0.06%) ▲|GEV1,091.57+16.31 (+1.52%) ▲|GILD129.83-5.01 (-3.72%) ▼|GM77.85+1.20 (+1.57%) ▲|GOOG355.03-1.21 (-0.34%) ▼|GOOGL357.18-1.71 (-0.48%) ▼|GS1,055.18-0.79 (-0.07%) ▼|HD343.30+4.57 (+1.35%) ▲|HON226.42+3.00 (+1.34%) ▲|IBM287.56-7.74 (-2.62%) ▼|INTC109.84-2.70 (-2.40%) ▼|INTU274.96+1.58 (+0.58%) ▲|ISRG406.78-4.77 (-1.16%) ▼|JNJ256.98-2.12 (-0.82%) ▼|JPM336.47+1.00 (+0.30%) ▲|KO83.49+0.86 (+1.04%) ▲|LIN529.79+4.23 (+0.80%) ▲|LLY1,188.58-28.37 (-2.33%) ▼|LMT523.22+4.96 (+0.96%) ▲|LOW211.63-1.37 (-0.64%) ▼|LRCX350.33-2.84 (-0.80%) ▼|MA526.74+3.54 (+0.68%) ▲|MCD274.60-1.89 (-0.68%) ▼|MDLZ58.83+0.53 (+0.91%) ▲|MDT83.87+1.48 (+1.80%) ▲|META669.21+37.73 (+5.97%) ▲|MMM157.52+2.18 (+1.40%) ▲|MO71.79+0.20 (+0.28%) ▲|MRK123.54-1.53 (-1.22%) ▼|MS222.28+0.15 (+0.07%) ▲|MSFT385.10+0.74 (+0.19%) ▲|MU979.30-12.34 (-1.24%) ▼|NEE87.96+0.86 (+0.99%) ▲|NFLX73.37-2.10 (-2.78%) ▼|NKE44.37+1.59 (+3.72%) ▲|NOW107.71-1.13 (-1.04%) ▼|NVDA210.96+8.18 (+4.03%) ▲|ORCL140.64-3.08 (-2.14%) ▼|PEP137.38-0.48 (-0.35%) ▼|PFE24.17-0.08 (-0.33%) ▼|PG147.04+0.19 (+0.13%) ▲|PLTR126.79-2.25 (-1.74%) ▼|PM181.62+0.45 (+0.25%) ▲|QCOM189.16-1.95 (-1.02%) ▼|RTX195.93+0.73 (+0.37%) ▲|SBUX106.01-0.40 (-0.38%) ▼|SCHW103.12+1.21 (+1.19%) ▲|SO95.61+0.44 (+0.46%) ▲|SPG218.77-0.94 (-0.43%) ▼|T21.13+0.37 (+1.77%) ▲|TMO527.05+2.34 (+0.45%) ▲|TMUS187.61+6.13 (+3.38%) ▲|TSLA407.76+1.21 (+0.30%) ▲|TXN311.46+2.93 (+0.95%) ▲|UBER74.54+0.19 (+0.26%) ▲|UNH424.62-7.06 (-1.64%) ▼|UNP286.96+1.92 (+0.67%) ▲|UPS112.47+1.73 (+1.56%) ▲|USB62.41+0.51 (+0.82%) ▲|V348.97+0.77 (+0.22%) ▲|VZ42.12+0.59 (+1.41%) ▲|WFC87.16+0.25 (+0.29%) ▲|WMT113.90+1.69 (+1.51%) ▲|XOM138.88+1.42 (+1.03%) ▲|AAPL315.32-0.90 (-0.28%) ▼|ABBV248.08-1.83 (-0.73%) ▼|ABT93.93-0.47 (-0.50%) ▼|ACN135.23-3.83 (-2.75%) ▼|ADBE223.64+0.99 (+0.44%) ▲|AMAT602.50+13.84 (+2.35%) ▲|AMD557.89+11.17 (+2.04%) ▲|AMGN363.39-0.23 (-0.06%) ▼|AMT168.59+3.59 (+2.18%) ▲|AMZN245.34-1.70 (-0.69%) ▼|AVGO399.97-1.14 (-0.28%) ▼|AXP350.58+3.86 (+1.11%) ▲|BA222.28-0.83 (-0.37%) ▼|BAC59.67+0.42 (+0.71%) ▲|BKNG178.39+2.87 (+1.64%) ▲|BLK1,036.11+16.43 (+1.61%) ▲|BMY57.58-0.36 (-0.62%) ▼|BNY151.92-0.34 (-0.22%) ▼|BRK-B493.71-1.74 (-0.35%) ▼|C140.79+1.22 (+0.87%) ▲|CAT952.41+14.02 (+1.49%) ▲|CL92.24+1.23 (+1.35%) ▲|CMCSA23.57+0.23 (+0.96%) ▲|COF201.52+1.42 (+0.71%) ▲|COP109.04+1.02 (+0.94%) ▲|COST916.25+3.28 (+0.36%) ▲|CRM163.32+0.82 (+0.50%) ▲|CSCO121.31+3.00 (+2.54%) ▲|CVS104.15+1.34 (+1.30%) ▲|CVX176.40+2.35 (+1.35%) ▲|DE586.86-6.04 (-1.02%) ▼|DHR199.05+3.07 (+1.57%) ▲|DIS95.62-0.55 (-0.57%) ▼|DUK125.48+0.22 (+0.18%) ▲|EMR138.88+1.08 (+0.78%) ▲|FDX314.69+3.85 (+1.24%) ▲|GD375.06+0.46 (+0.12%) ▲|GE359.27+0.23 (+0.06%) ▲|GEV1,091.57+16.31 (+1.52%) ▲|GILD129.83-5.01 (-3.72%) ▼|GM77.85+1.20 (+1.57%) ▲|GOOG355.03-1.21 (-0.34%) ▼|GOOGL357.18-1.71 (-0.48%) ▼|GS1,055.18-0.79 (-0.07%) ▼|HD343.30+4.57 (+1.35%) ▲|HON226.42+3.00 (+1.34%) ▲|IBM287.56-7.74 (-2.62%) ▼|INTC109.84-2.70 (-2.40%) ▼|INTU274.96+1.58 (+0.58%) ▲|ISRG406.78-4.77 (-1.16%) ▼|JNJ256.98-2.12 (-0.82%) ▼|JPM336.47+1.00 (+0.30%) ▲|KO83.49+0.86 (+1.04%) ▲|LIN529.79+4.23 (+0.80%) ▲|LLY1,188.58-28.37 (-2.33%) ▼|LMT523.22+4.96 (+0.96%) ▲|LOW211.63-1.37 (-0.64%) ▼|LRCX350.33-2.84 (-0.80%) ▼|MA526.74+3.54 (+0.68%) ▲|MCD274.60-1.89 (-0.68%) ▼|MDLZ58.83+0.53 (+0.91%) ▲|MDT83.87+1.48 (+1.80%) ▲|META669.21+37.73 (+5.97%) ▲|MMM157.52+2.18 (+1.40%) ▲|MO71.79+0.20 (+0.28%) ▲|MRK123.54-1.53 (-1.22%) ▼|MS222.28+0.15 (+0.07%) ▲|MSFT385.10+0.74 (+0.19%) ▲|MU979.30-12.34 (-1.24%) ▼|NEE87.96+0.86 (+0.99%) ▲|NFLX73.37-2.10 (-2.78%) ▼|NKE44.37+1.59 (+3.72%) ▲|NOW107.71-1.13 (-1.04%) ▼|NVDA210.96+8.18 (+4.03%) ▲|ORCL140.64-3.08 (-2.14%) ▼|PEP137.38-0.48 (-0.35%) ▼|PFE24.17-0.08 (-0.33%) ▼|PG147.04+0.19 (+0.13%) ▲|PLTR126.79-2.25 (-1.74%) ▼|PM181.62+0.45 (+0.25%) ▲|QCOM189.16-1.95 (-1.02%) ▼|RTX195.93+0.73 (+0.37%) ▲|SBUX106.01-0.40 (-0.38%) ▼|SCHW103.12+1.21 (+1.19%) ▲|SO95.61+0.44 (+0.46%) ▲|SPG218.77-0.94 (-0.43%) ▼|T21.13+0.37 (+1.77%) ▲|TMO527.05+2.34 (+0.45%) ▲|TMUS187.61+6.13 (+3.38%) ▲|TSLA407.76+1.21 (+0.30%) ▲|TXN311.46+2.93 (+0.95%) ▲|UBER74.54+0.19 (+0.26%) ▲|UNH424.62-7.06 (-1.64%) ▼|UNP286.96+1.92 (+0.67%) ▲|UPS112.47+1.73 (+1.56%) ▲|USB62.41+0.51 (+0.82%) ▲|V348.97+0.77 (+0.22%) ▲|VZ42.12+0.59 (+1.41%) ▲|WFC87.16+0.25 (+0.29%) ▲|WMT113.90+1.69 (+1.51%) ▲|XOM138.88+1.42 (+1.03%) ▲|
29 C
New York
Saturday, July 11, 2026

Tag: access

With the Potential for Extreme Heat, PSE&G Is Prepared and Urges Customers to Stay Safe and Energy Smart

Utility offers tips to stay cool and manage energy bills during high temperatures NEWARK, N.J., June 20, 2025 /PRNewswire/ -- With temperatures expected to climb this...

The American Diabetes Association Demonstrates Its Commitment to Curbing the Obesity Epidemic with Obesity Standards of Care

Symposium previews new content for Standards of Care in Overweight and Obesity, designed to improve patient care and outcomes CHICAGO, June 20, 2025 /PRNewswire/...

CREDIT UNIONS RALLY TO PROTECT TAX-EXEMPT STATUS, SAFEGUARDING 142 MILLION AMERICANS’ FINANCIAL FUTURE

ENOLA, Pa., June 20, 2025 /PRNewswire/ -- While much of the public debate in Washington focuses on high-profile issues, an equally important fight is...

Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

SC injection of VYVGART® is available as a vial or prefilled syringe and can be administered by a patient, caregiver, or healthcare professional SAN DIEGO,...

Dr. Konstantinos Zarkadas Unveils National Scholarship to Cultivate Next-Generation Medical Leaders

Prestigious Award to Empower Aspiring Physicians Across the United States
Prestigious Award to Empower Aspiring Physicians Across the United States

Aesthetic Surgery Journal Impact Factor Jumps Significantly

ASJ Open Forum Earns Second Consecutive Score, Signaling Steady Growth GARDEN GROVE, Calif., June 20, 2025 /PRNewswire/ -- The Aesthetic Society is proud to announce a...

123Invent Inventor Develops New Accessory for Nail & Staple Guns (CTK-1559)

PITTSBURGH, June 20, 2025 /PRNewswire/ -- "I thought there could be an improved way to hold an extra supply of staples or nails when...

2025 Online Firearm Sales Continue to Grow at Guns.com

Leading Online Retailer Continues to Revolutionize the Online Shopping Experience for Gun Owners, Manufacturers, and Local Dealers Nationwide BURNSVILLE, Minn., June 20, 2025 /PRNewswire/ --...

If you are legally blind and attempted to access www.fashionnova.com using screen reading software between February 26, 2018 and now, you may benefit from...

Announced by CPT Group, Inc. IRVINE, Calif., June 20, 2025 /PRNewswire/ -- CPT Group, Inc., announces that a settlement was reached in the class action...

SeaStar Medical Announces Pricing of Up to $8 Million Public Offering

$4 million upfront with up to an additional $4 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants
$4 million upfront with up to an additional $4 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants

iFFALCON Brings Its Art-Forward, High-Performance Smart TV to U.S. Homes

iFFALCON Launches Bezel-Less Premium Smart TV Backed by a Global TV Leader NEW YORK, June 20, 2025 /PRNewswire/ -- iFFALCON, a brand powered by one...

LightStyles + Builders Source Appliance Gallery is Costa Mesa’s Newest Luxury Showroom

Showroom Opening July, 2025 COSTA MESA, Calif., June 20, 2025 /PRNewswire/ -- LightStyles + Builders Source Appliance Gallery is pleased to announce the opening of its new...

SAM HOUSTON STAMPEDE CONCERT SERIES

Sam Houston Race Park welcomes back concerts at The Showgrounds HOUSTON, June 20, 2025 /PRNewswire/ -- H-Town, you asked, and we listened. Concerts are back...

Cancer Monoclonal Antibody Collaboration and Licensing Agreements Analysis Report and Directory 2016-2025

Dublin, June 20, 2025 (GLOBE NEWSWIRE) -- The "Cancer Monoclonal Antibody Collaboration and Licensing Deals 2016-2025" has been added to ResearchAndMarkets.com's offering.

This report contains a comprehensive listing of 632 cancer monoclonal antibody deals announced since 2016 including financial terms where available, as well as links to online deal records of actual cancer monoclonal antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Fully revised and updated, the report provides details of cancer monoclonal antibody deals from 2016 to 2025. Cancer Monoclonal Antibody Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the cancer monoclonal antibody deals entered into by the world's leading biopharma companies.

The report provides a detailed understanding and analysis of how and why companies enter cancer monoclonal antibody deals. These deals tend to be multicomponent, starting with collaborative R&D and commercialization of outcomes. The report includes collaboration, development, research, and licensing deals.

The initial chapters of this report provide an orientation of cancer monoclonal antibody dealmaking. It starts with an introduction to the report, followed by an overview of the trends in cancer monoclonal antibody dealmaking since 2016. The chapters progress by covering the leading deals by headline value, listing the top 25 most active companies in this domain, and reviewing detailed and comprehensive accounts of deals signed and announced since January 2016, categorized by technology type in focus.

The report also includes numerous tables and figures that illustrate the trends and activities in cancer monoclonal antibody deal making since 2016. In addition, a comprehensive deal directory is provided organized by company A-Z, deal type, and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Cancer Monoclonal Antibody Collaboration and Licensing Deals provides the reader with the following key benefits:

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsAccess